Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry

(2013) H. Chambost et al.   HAEMOPHILIA

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

(2013) R. Ljung et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers

(2013) G. Golor et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors

(2012) P. Salaj et al.   HAEMOPHILIA

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

(2012) J. N. MAHLANGU et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Vatreptacog Alfa from Conception to Clinical Proof of Concept

(2012) Egon Persson et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)

(2011) A. TIEDE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

(2011) J. MØSS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

(2011) ERICH V. DE PAULA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A

(2010) Donald F Brophy et al.   BLOOD COAGULATION & FIBRINOLYSIS

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

(2010) Shunmugaperumal Tamilvanan et al.   JOURNAL OF DRUG TARGETING

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

(2008) R. YATUV et al.   HAEMOPHILIA

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

(2008) T. ABSHIRE et al.   HAEMOPHILIA

Single 270 μg kg−1-dose rFVIIa vs. standard 90 μg kg−1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

(2008) G. YOUNG et al.   HAEMOPHILIA

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

(2008) J. MØSS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS